Tagrisso (osimertinib tablets – AstraZeneca) — Cigna
Non-Small Cell Lung Cancer – Post Tumor Resection, Adjuvant Therapy
Initial criteria
- Patient age ≥ 18 years
- Patient has completely resected disease
- Patient has EGFR exon 19 deletion or exon 21 (L858R) substitution mutation as detected by an approved test
- Patient meets ONE of the following (i or ii):
- i. Patient had received previous adjuvant chemotherapy
- ii. Patient is ineligible to receive platinum-based chemotherapy
Approval duration
3 years (total)